GLP-1 agonists, medications originally formulated to treat diabetes, have gained traction as prescription drugs for weight loss. On this episode, medical researcher and patient advocate Ragen Chastain discusses what healthcare providers should be sharing with their patients about the risks and efficacy of Wegovy and Zepbound.
{{ loadingHeading }}
{{ loadingSubHeading }}
Your session has expired.
Please reload the page and try again.
Membership
HFMA empowers healthcare financial professionals with the tools and resources they need to overcome today's toughest challenges.
Already a Member?
Community
Connect with your healthcare finance community online or in-person.
Sign up for HFMA`s monthly e-newsletter, The Buzz.
E-Newsletter Subscriptions
Member benefits delivered to your inbox!
Healthcare finance content, event info and membership offers delivered to your inbox.
Check out our specialized e-newsletters for healthcare finance pros.
Member benefits delivered to your inbox! Check out our specialized e-newsletters for healthcare finance pros.
Get trusted analysis and direction from the experts at HFMA.
All the healthcare finance news and information you need to stay current.
In-person, online. Professional development designed with you in mind.
Supporting your career, every step of the way.
Sign up for The Buzz
Healthcare finance content, event info and membership offers delivered to your inbox. Sign up for HFMA’s monthly e-newslettter, The Buzz.